DOCSLIB.ORG

Idiopathic Intracranial Hypertension: Consensus Guidelines On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Idiopathic Intracranial Hypertension: Consensus Guidelines On General Neurology J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2017-317440 on 14 June 2018. Downloaded from REVIEW Idiopathic intracranial hypertension: consensus guidelines on management Susan P Mollan,1,2 Brendan Davies,3 Nick C Silver,4 Simon Shaw,5 Conor L Mallucci,6,7 Benjamin R Wakerley,8,9 Anita Krishnan,4 Swarupsinh V Chavda,10 Satheesh Ramalingam,10 Julie Edwards,11,12 Krystal Hemmings,13 Michelle Williamson,13 Michael A Burdon,2 Ghaniah Hassan-Smith,1,12 Kathleen Digre,14 Grant T Liu,15 Rigmor Højland Jensen,16 Alexandra J Sinclair1,2,12,17 ► Additional material is ABSTRact contains information that will be of interest to those published online only. To view The aim was to capture interdisciplinary expertise from a in primary care and other healthcare professionals. please visit the journal online large group of clinicians, reflecting practice from across The increasing economic burden of IIH has been (http:// dx. doi. org/ 10. 1136/ 1 2 jnnp- 2017- 317440). the UK and further, to inform subsequent development of highlighted by a number of groups. Clear guid- a national consensus guidance for optimal management ance will help educate the attending doctors to For numbered affiliations see of idiopathic intracranial hypertension (IIH). manage these patients appropriately. This will help end of article. Methods Between September 2015 and October reduce the repeat unsolicited emergency hospital 2017, a specialist interest group including neurology, attendances and reduce IIH-related disability. Correspondence to There are a number of ongoing clinical trials in IIH Dr Alexandra J Sinclair, neurosurgery, neuroradiology, ophthalmology, nursing, Metabolic Neurology, Institute primary care doctors and patient representatives (https://www. clinicaltrials.gov/) and as evidence for of Metabolism and Systems met. An initial UK survey of attitudes and practice medical and surgical management evolves in IIH Research, University of in IIH was sent to a wide group of physicians and this document will require timely updates. Birmingham, Birmingham B15 surgeons who investigate and manage IIH regularly. 2TT, UK; a. b. sinclair@ bham. ac. uk A comprehensive systematic literature review was BacKGROUND performed to assemble the foundations of the copyright. Received 12 November 2017 statements. An international panel along with four IIH occurs predominantly in women and although Revised 6 February 2018 national professional bodies, namely the Association of the underlying pathogenesis is not fully under- Accepted 7 February 2018 3 British Neurologists, British Association for the Study of stood, it has a striking association with obesity. Headache, the Society of British Neurological Surgeons The combination of raised intracranial pressure, and the Royal College of Ophthalmologists critically without hydrocephalus or mass lesion, normal cere- reviewed the statements. brospinal fluid (CSF) composition and where no Results Over 20 questions were constructed: one based underlying aetiology is found are accepted criteria 4 on the diagnostic principles for optimal investigation for the diagnosis of IIH. The overall age-adjusted of papilloedema and 21 for the management of IIH. and gender-adjusted annual incidence is increasing Three main principles were identified: (1) to treat the and was reported to be 2.4 per 100 000 within the 5 http://jnnp.bmj.com/ underlying disease; (2) to protect the vision; and (3) to last decade (2002–2014). minimise the headache morbidity. Statements presented The majority of patients presenting with IIH have provide insight to uncertainties in IIH where research symptoms that include a headache that is progres- opportunities exist. sively more severe and frequent, as defined by Inter- Conclusions In collaboration with many different national Classification of Headache Disorders, 3rd 6 specialists, professions and patient representatives, edition (ICHD-3) (figure 1). The headache pheno- we have developed guidance statements for the type is highly variable and may mimic other primary investigation and management of adult IIH. headache disorders. Other symptoms may include on September 30, 2021 by guest. Protected transient visual obscurations (unilateral or bilateral darkening of the vision typically seconds), pulsa- tile tinnitus, back pain, dizziness, neck pain, visual SCOPE blurring, cognitive disturbances, radicular pain and This is a consensus document to provide practical typically horizontal diplopia (figure 1A)3: none of information for best practice in uniform investiga- which are pathognomonic for IIH.7 Investigation tion and treatment strategies based on current liter- and management depends on symptoms and signs ature and opinion from a specialist interest group and requires an interdisciplinary team approach. (SIG) for adult idiopathic intracranial hypertension For the individual patient, some can have (IIH). This should increase awareness of IIH among permanent visual loss.8 Chronic headache signifi- To cite: Mollan SP, Davies B, clinicians and improve outcomes for patients. cantly impacts quality of life9 10 with over half of Silver NC, et al. J Neurol The target audience for this statement includes patients with IIH reporting ongoing headaches at Neurosurg Psychiatry Epub 11 ahead of print: [please neurologists, ophthalmologists, neurosurgeons, 12 months. include Day Month Year]. radiologists, emergency medicine specialists, physi- Clinical uncertainty exists, and IIH can be doi:10.1136/jnnp-2017- cians, ear nose and throat specialists and other misdiagnosed.12 The 2015 Cochrane review has 317440 clinicians who investigate and manage IIH. It also concluded that there is lack of evidence to guide Mollan SP, et al. J Neurol Neurosurg Psychiatry 2018;0:1–13. doi:10.1136/jnnp-2017-317440 1 General Neurology J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2017-317440 on 14 June 2018. Downloaded from Figure 1 Consensus in diagnosing IIH. (A) Frequency of IIH symptoms reported, adapted from Markey et al.3 (B) IIH diagnostic criteria, adapted copyright. from Friedman et al.4 (C) IIHWOP diagnostic criteria, adapted from Friedman et al.4 (D) Headache attributed to IIH, as described by the International Classification of Headache Disorders, 3rd edition (beta version) (ICHD-3 beta).6 (E) Line figure detailing the consensus of the interpretation of LP opening pressure. Uncertainty: it needs to be recognised that this is a single LP OP measurement; and after raised ICP what is then a normal ICP for this population on repeat LP readings is unknown. CSF, cerebrospinal fluid; IIH, idiopathic intracranial hypertension; LP, lumboperitoneal. pharmacological treatment in IIH.13 Randomised clinical trials and the British Association for the Study of Headache (BASH). are currently infrequent in this field due to the rarity of the Where there was disagreement in statement recommendations, disease, the lack of understanding of the underlying patholog- these were debated within the SIG, and wording was altered ical mechanisms and limited disease-modifying therapies. accordingly. http://jnnp.bmj.com/ Specifically, to improve local outcomes for patients with IIH, METHODS audit recommendations are enclosed (online supplementary An SIG was formed, including neurology, neurosurgery, appendix 2). This document will need to be revised regularly as neuroradiology, ophthalmology, nursing, primary care doctors new evidence emerges in the field of IIH. Definitions used in the 14–17 and patient representatives. All clinicians had expertise in guidance are presented in table 2. managing IIH. An initial UK survey of attitudes and practice in IIH was sent to a wide group of consultants who investigate on September 30, 2021 by guest. Protected and manage IIH regularly: these included neurology, neuro- DIagnOSTIC PRINCIPLES surgery, neuro-ophthalmology and neuroradiology. A compre- For optimal investigation of patients with papilloedema, there hensive systemic literature review was performed to assemble must be clear communication between clinicians for seamless the foundations of the statements. Rigorous controlled data joint investigation between the various specialities. The aims of are sparse in IIH, and therefore, a consensus-based guide is investigations of papilloedema are to: presented. Questions were formulated (table 1). An anony- 1. find any underlying treatable cause in a timely manner mous modified Delphi process was used to obtain consensus on 2. protect the vision and ensure timely re-examination when guidance statements. All statements below obtained consensus vision is at risk of 75% or above from the SIG and wider Delphi group. A 3. enable onward care of the patient with the input from the completed AGREE statement is found as supplementary data most appropriate experienced clinician. (online supplementary appendix 1). An international panel of experts in IIH (RHJ, GTL and KD) Q1 How should papilloedema be investigated? (figure 2) reviewed the document and a wider consultation was made with ► Blood pressure must be measured to exclude malignant professional bodies namely the Association of British Neurol- hypertension, as defined as a diastolic blood pressure greater ogists (ABN), the Society of British Neurological Surgeons than or equal to 120 mm Hg or systolic blood pressure (SBNS), the Royal College of Ophthalmologists (RCOphth) greater than or equal to 180 mm Hg.18 2 Mollan SP, et al. J Neurol Neurosurg Psychiatry 2018;0:1–13. doi:10.1136/jnnp-2017-317440 General Neurology J Neurol
Load more

Recommended publications
  • Status Epilepticus Clinical Pathway
    JOHNS HOPKINS ALL CHILDREN’S HOSPITAL Status Epilepticus Clinical Pathway 1 Johns Hopkins All Children's Hospital Status Epilepticus Clinical Pathway Table of Contents 1. Rationale 2. Background 3. Diagnosis 4. Labs 5. Radiologic Studies 6. General Management 7. Status Epilepticus Pathway 8. Pharmacologic Management 9. Therapeutic Drug Monitoring 10. Inpatient Status Admission Criteria a. Admission Pathway 11. Outcome Measures 12. References Last updated: July 7, 2019 Owners: Danielle Hirsch, MD, Emergency Medicine; Jennifer Avallone, DO, Neurology This pathway is intended as a guide for physicians, physician assistants, nurse practitioners and other healthcare providers. It should be adapted to the care of specific patient based on the patient’s individualized circumstances and the practitioner’s professional judgment. 2 Johns Hopkins All Children's Hospital Status Epilepticus Clinical Pathway Rationale This clinical pathway was developed by a consensus group of JHACH neurologists/epileptologists, emergency physicians, advanced practice providers, hospitalists, intensivists, nurses, and pharmacists to standardize the management of children treated for status epilepticus. The following clinical issues are addressed: ● When to evaluate for status epilepticus ● When to consider admission for further evaluation and treatment of status epilepticus ● When to consult Neurology, Hospitalists, or Critical Care Team for further management of status epilepticus ● When to obtain further neuroimaging for status epilepticus ● What ongoing therapy patients should receive for status epilepticus Background: Status epilepticus (SE) is the most common neurological emergency in children1 and has the potential to cause substantial morbidity and mortality. Incidence among children ranges from 17 to 23 per 100,000 annually.2 Prevalence is highest in pediatric patients from zero to four years of age.3 Ng3 acknowledges the most current definition of SE as a continuous seizure lasting more than five minutes or two or more distinct seizures without regaining awareness in between.
    [Show full text]
  • Stand up to Chronic Migraine with Botox®
    #1 PRESCRIBED BRANDED TREATMENT FOR CHRONIC MIGRAINE* Chronic Migraine DON’T LIE DOWN BOTOX ® STAND UP TO Prevention CHRONIC MIGRAINE® WITH BOTOX Treatment Experience Treatment *Truven Health MarketScan Data, October 2010-April 2017. Prevent Headaches and Migraines Before They Even Start BOTOX ® BOTOX® prevents on average 8 to 9 headache days and migraine/probable migraine days a month (vs 6 to 7 for placebo) Savings Program For adults with Chronic Migraine, 15 or more headache days a month, each lasting 4 hours or more. BOTOX® is not approved for adults with migraine who have 14 or fewer headache days a month. Indication • Spread of toxin effects. The effect of botulinum toxin may affect areas BOTOX® is a prescription medicine that is injected to prevent headaches in adults away from the injection site and cause serious symptoms including: loss of with chronic migraine who have 15 or more days each month with headache strength and all-over muscle weakness, double vision, blurred vision and lasting 4 or more hours each day in people 18 years or older. drooping eyelids, hoarseness or change or loss of voice, trouble saying words It is not known whether BOTOX® is safe or effective to prevent headaches clearly, loss of bladder control, trouble breathing, trouble swallowing. in patients with migraine who have 14 or fewer headache days each month There has not been a confirmed serious case of spread of toxin effect away from (episodic migraine). the injection site when BOTOX® has been used at the recommended dose to IMPORTANT SAFETY INFORMATION treat chronic migraine. Resources BOTOX® may cause serious side effects that can be life threatening.
    [Show full text]
  • Hydrocephalus and Shunts
    Hydrocephalus and Shunts Information for patients 2 What is hydrocephalus? The brain is surrounded by fluid, called CSF - Cerebrospinal fluid. The CSF provides some protection for the brain. The brain makes CSF in special fluid-filled spaces called ventricles. The ventricles link to each other by a system of channels through which the CSF flows and eventually leaves to surround the whole brain and spinal cord. The CSF is then taken back into the blood-stream by special channels beside the major veins on the inside of the skull. These are called arachnoid granulations. Figure 1 - Diagram of the brain showing normal CSF pathways 3 Hydrocephalus is a condition in which the CSF builds up within the brain. There are a number of causes of this: 1. The fluid pathways may be blocked or narrowed so that fluid cannot flow adequately. The causes of this blockage can include scarring, a variation in the development of the fluid pathways (present from birth) or sometimes by a tumour which blocks the CSF flow. 2. Sometimes the fluid collection channels (arachnoid granulations) can become blocked and stop working - in a similar manner to how leaves can block a drain. This can happen following an infection or a bleed (haemorrhage). As a result of this block in fluid flow, CSF builds up inside the brain, resulting in an increase in pressure. As a result of this patients most commonly report symptoms of headaches, nausea and vomiting, but problems with balance and short term memory have also been reported. There is another group of patients who do not fit into the patterns described above.
    [Show full text]
  • The Migraine-Epilepsy Syndrome
    medigraphic Artemisaen línea Arch Neurocien (Mex) Vol 11, No. 4: 282-287, 2006 The Migraine- Epilepsy Syndrome Arch Neurocien (Mex) Vol. 11, No. 4: 282-287, 2006 Artículo de revisión ©INNN, 2006 de caso The migraine-epilepsy syndrome Enrique Otero Siliceo†, Fernando Zermeño EL SINDROME MIGRAÑA-EPILEPSIA represent a neural exitation. Since that the glutamate has in important rol in both patologys depending of the part of the brain more affected the symptoms might RESUMEN vary from visual to abdominal phemomena. La migraña y la epilepsia tienen varios puntos en común Key words: migraine epilepsy, EEG abnormalities, sintomática clínica y genéticamente lo que ha sido glutamate, diagnosis. postulado por más de cien años. El fenómeno referido como migraña-epilepsia sugiere que exista una he first steps of a practical, approach by patofisiología común. El síndrome de migraña o physicians in recognizing and treating neuro- epilepsia tiene fenómenos comunes de dolor adominal T logic diseases are to recognithat there are jaqueca anormalidades del EE y respuesta a droga various overlaps between migraine and epilepsy. antiepilépticas. En ocasiones el paciente puede tener Epileptic seizures and classic migraine episodes may un ataque migrañoso o una convulsión o en otras occur in the same patient. Migraine and epilepsy share ambas. La comorbilidad puede explicarse por estados several genetic, clinical, evolutive and neurophysio- de hiperrexcitabilidad neural. Alteraciones electroen- logic features. A relationship between epilepsy and cefalográficas son comunes en estos estados. En migraine has been postulated for over a hundred years apariencia el glutamato tiene un papel importante tanto and the syndrome of Migraine-Epilepsy illustrates this en la migraña como en la epilepsia.
    [Show full text]
  • Journal of Neurological Disorders DOI: 10.4172/2329-6895.1000275 ISSN: 2329-6895
    olog eur ica N l D f i o s l o a r n d r e u r s o J Derakhshan, J Neurol Disord 2016, 4:4 Journal of Neurological Disorders DOI: 10.4172/2329-6895.1000275 ISSN: 2329-6895 Research Article Open Access Successful Opioid Monotherapy in Migralepsy: A Case Series Iraj Derakhshan* Department of Neurology, Case Western Reserve and Cincinnati Universities, Ohio, USA *Corresponding author: Iraj Derakhshan, Associate Professor, Department of Neurology, Case Western Reserve and Cincinnati Universities, Ohio, 205 Cyrus Drive, Charleston West Virginia, 25314, USA, Tel: 304 345 5174; E-mail: [email protected] Rec date: June 10, 2016; Acc date: July 06, 2016; Pub date: July 10, 2016 Copyright: © 2016 Derakhshan I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: There is a consensus that migraine and epilepsy are comorbid conditions. The novel concept explored and developed in this case series is that of the primacy of headaches in generating seizures in those patients suffering from migraine-triggered epilepsy (i.e., migralepsy). As demonstrated in the five cases descried here, much like the effect of ketogenic-diet on migraine-triggered epilepsy, once the migraine headaches were completely suppressed after adopting daily scheduled opioid therapy the seizures stopped from occurring, but they returned with the recurrence of the migraines once the patients had stopped their daily opiate regimen for any reason. Clinical implications: The above pharmacological scenario is reminiscent of a similar but naturalistic course of events as described in reports concerning the salutary effects of ketogenic diet, or restoration of sleep, in cases of migraine-triggered epilepsy.
    [Show full text]
  • Migraine Mimics
    ISSN 0017-8748 Headache doi: 10.1111/head.12518 © 2015 American Headache Society Published by Wiley Periodicals, Inc. Expert Opinion Migraine Mimics Randolph W. Evans, MD The symptoms of migraine are non-specific and can be present in many other primary and secondary headache disorders, which are reviewed. Even experienced headache specialists may be challenged at times when diagnosing what appears to be first or worst, new type, migraine status, and chronic migraine. Key words: migraine, migraine mimic, symptomatic migraine, hemicrania continua (Headache 2015;55:313-322) The symptoms of migraine are non-specific and She had seen 2 headache specialists previously. can be present in many other primary and secondary She had been tried on sumatriptan p.o. and subcuta- headache disorders.1,2 Even experienced headache neously, diclofenac powder, ketorolac oral and intra- specialists may be challenged at times when diagnos- muscular, dihydroergotamine nasal spray, and had an ing what appears to be first or worst, new type, occipital nerve block without benefit. Gabapentin migraine status, and chronic migraine. Another diag- and pregabalin did not help. She was placed on indo- nosis may be responsible when physicians use the term methacin 75 mg sustained release once a day for 8 “atypical migraine.” days without benefit. Prednisone 60 mg daily for 10 days did not help.An intravenous dihydroergotamine CASE HISTORIES regimen for 5 days did not help. Case 1.—This 48-year-old woman was seen for a A magnetic resonance imaging (MRI) and mag- third opinion with a 20-year history of only menstrual netic resonance angiogram (MRA) of the brain and headaches always preceded by a visual aura followed cervical spine and magnetic resonance venogram by a generalized throbbing with an intensity of 5–6/10 (MRV) of the brain were negative.
    [Show full text]
  • Parkinsonian Symptoms in Normal Pressure Hydrocephalus: a Population-Based Study
    http://www.diva-portal.org This is the published version of a paper published in Journal of Neurology. Citation for the original published paper (version of record): Molde, K., Söderström, L., Laurell, K. (2017) Parkinsonian symptoms in normal pressure hydrocephalus: a population-based study. Journal of Neurology, 264(10): 2141-2148 https://doi.org/10.1007/s00415-017-8598-5 Access to the published version may require subscription. N.B. When citing this work, cite the original published paper. Permanent link to this version: http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-142915 J Neurol (2017) 264:2141–2148 DOI 10.1007/s00415-017-8598-5 ORIGINAL COMMUNICATION Parkinsonian symptoms in normal pressure hydrocephalus: a population‑based study Karin Molde1 · Lars Söderström1 · Katarina Laurell1 Received: 3 June 2017 / Revised: 17 August 2017 / Accepted: 18 August 2017 / Published online: 6 September 2017 © The Author(s) 2017. This article is an open access publication Abstract It may be challenging to diferentiate normal liberal use of neuroradiological imaging when investigating pressure hydrocephalus (NPH) from neurodegenerative a patient with parkinsonian features. disorders such as Parkinson’s disease. In this population- based study, we wanted to describe the frequency of par- Keywords Normal pressure hydrocephalus · kinsonian symptoms among individuals with and without Hydrocephalus · Parkinsonism · Parkinson’s disease · NPH, and whether the motor examination part of the Unifed UPDRS Parkinson’s Disease Rating Scale (UPDRS-m) score difers between these groups. Furthermore, we wanted to fnd out whether there was a relationship between UPDRS-m score, Introduction NPH symptoms, and radiological signs of NPH.
    [Show full text]
  • DIAGNOSTICS and THERAPY of INCREASED INTRACRANIAL PRESSURE in ISCHEMIC STROKE
    DIAGNOSTICS and THERAPY of INCREASED INTRACRANIAL PRESSURE in ISCHEMIC STROKE Erich Schmutzhard INNSBRUCK, AUSTRIA e - mail: erich.schmutzhard@i - med.ac.at Neuro - ICU Innsbruck Conflict of interest : Speaker‘s honoraria from ZOLL Medical and Honoraria for manuscripts from Pfizer Neuro - ICU Innsbruck OUTLINE Introduction Definition: ICP, CPP, PbtiO2, metabolic monitoring, lactate , pyruvate , brain temperature etc Epidemiology of ischemic stroke and ICP elevation in ischemic stroke ACM infarction and the role of collaterals and/ or lack of collaterals for ICP etc Hydrocephalus in posterioir fossa ( mainly cerebellar ) infarction Diagnosis of ICP etc Monitoring of ICP etc Therapeutic management : decompressive craniectomy – meta - analysis of DESTINY HAMLET und co deepening of analgosedation , ventilation , hyperventilation , osmotherapy , CPP - oriented th , MAP management , hypothermia , prophylactic normothermia , external ventricular drainage Neuro - ICU Innsbruck Introduction - Malignant cerebral edema following ischemic stroke is life threatening. - The pathophysiology of brain edema involves failure of the sodium - potassium adenosine triphosphatase pump and disruption of the blood - brain barrier, leading to cytotoxic edema and cellular death. - The Monro - Kellie doctrine clearlc states that - since the brain is encased in a finite space - increased intracranial pressure (ICP) due to cerebral edema can result in herniation through the foramen magnum and openings formed by the falx and tentorium. - Moreover, elevated ICP can cause secondary brain ischemia through decreased cerebral perfusion and blood flow, brain tissue hypoxia, and metabolic crisis. - Direct cerebrovascular compression caused by brain tissue shifting can lead to secondary infarction, especially in the territories of the anterior and posterior cerebral artery. - Tissue shifts can also stretch and tear cerebral vessels, causing intracranial hemorrhage such as Duret’s hemorrhage of the brainstem.
    [Show full text]
  • Hydrocephalus Patient Information Guide Experience Life Without Boundaries
    Hydrocephalus Patient Information Guide Experience Life Without Boundaries Aesculap Neurosurgery 2 Table of Contents Foreword Page 4 About Us Page 5 What Is Hydrocephalus Page 6 Types Of Hydrocephalus Page 7 What You Should Know Page 8 Diagnosis Page 9 Treatment/Goal/Surgical Procedure Page 10 Complications Page 10 Prognosis/Helpful Sites Page 11 The Aesculap Shunts Page 12 Medical Definitions Page 13 3 Foreword The intention of this booklet is to provide information to patients, family members, caregivers and friends on the subject of hydrocephalus. The information provided is a general overview of the diagnosis and treatment of hydrocephalus and other conditions associated with hydrocephalus. About us History Aesculap AG (Germany) was founded in 1867 by Gottfried Jetter, a master craftsman trained in surgical instrument and cutlery techniques. Jetter’s original workshop, located in Tuttlingen, Germany, is the same location where Aesculap world headquarters resides today. The employee count has increased over the years (3,000+ employees), and the number of instrument patterns has grown from a select few to over 17,000; however, the German standard for quality and pattern consistency remains the same. Prior to 1977, many of the instruments sold in America by competing companies were sourced from Aesculap in Tuttlingen. In response to the United States customer demand for Aesculap quality surgical instruments, Aesculap, Inc. (U.S.) was established in 1977. Headquartered in Center Valley, Pennsylvania, with over one hundred direct nationwide sales representatives, Aesculap, Inc. currently supports the marketing, sales and distribution of Aesculap surgical instrumentation in the U.S. In order to support the company’s continued growth and provide the service and quality which customers have come to expect, Aesculap relocated the corporate offices from San Francisco to Center Valley, Pennsylvania.
    [Show full text]
  • Ventriculoperitoneal Shunts in the Emergency Department: a Review
    Open Access Review Article DOI: 10.7759/cureus.6857 Ventriculoperitoneal Shunts in the Emergency Department: A Review Michael Ferras 1 , Nicholas McCauley 1 , Trilok Stead 2 , Latha Ganti 3, 4, 5 , Bobby Desai 6 1. Emergency Medicine, Ocala Regional Medical Center, University of Central Florida, Ocala, USA 2. Emergency Medicine, Trinity Preparatory School, Winter Park, USA 3. Emergency Medicine, Envision Physician Services, Orlando, USA 4. Emergency Medicine, University of Central Florida College of Medicine/Hospital Corporation of America Graduate Medical Education Consortium of Greater Orlando, Orlando, USA 5. Emergency Medicine, Polk County Fire Rescue, Bartow, USA 6. Emergency Medicine, Ocala Regional Medical Center, University of Central Florida College of Medicine, Ocala, USA Corresponding author: Latha Ganti, [email protected] Abstract In this paper, we review the indications, complications, and pitfalls associated with ventriculoperitoneal (VP) shunts. As most VP shunt problems initially present to the emergency department, it is important for emergency physicians to be well-versed in managing them. In the article, the possible reasons for shunt failure are explored and summarized using an infographic. We also examine potential clinical presentations of VP shunt failure. Categories: Emergency Medicine, Neurosurgery Keywords: ventriculoperitoneal shunts Introduction And Background Emergency department physicians usually see a large number of patients with medical maladies managed by the aid of instrumentation or hardware such as a ventriculoperitoneal (VP) shunt. While patients have shunts placed for multiple reasons, it is important for emergency service providers to know how to evaluate, troubleshoot, and treat those with VP shunt complications. An estimated 30,000 VP shunt procedures are performed yearly in the United States [1].
    [Show full text]
  • Symptoms and Signs of Progressive Hydrocephalus
    Arch Dis Child: first published as 10.1136/adc.64.1.124 on 1 January 1989. Downloaded from Archives of Disease in Childhood, 1989, 64, 124-128 Symptoms and signs of progressive hydrocephalus M KIRKPATRICK, H ENGLEMAN, AND R A MINNS Department of Neurology, Royal Hospital for Sick Children, Edinburgh SUMMARY The clinical features of 107 cases of children with hydrocephalus and measured raised intraventricular pressure were analysed retrospectively. Fifty one children had recently been diagnosed as having hydrocephalus, and the remainder had had shunts injected to direct the cerebrospinal fluid. The most common symptoms in the group were vomiting, behavioural changes, drowsiness, and headaches. The most common clinical signs were inappropriately increasing occipitofrontal head circumferences, tense anterior fontanelles, splayed sutures, and distension of the scalp veins. Half the infantile cases of hydrocephalus were without symptoms, and a quarter of the cases with cerebrospinal fluid shunts and measured raised intraventricular pressure were without signs. There were no fewer than 33 different clinical signs including several unusual ones, such as macular rash and sweating. We believe that the presentation of hydrocephalus with raised intraventricular pressure is sufficiently variable, unusual, or even absent to justify the direct measurement of intracranial pressure. copyright. The classical adult presentation of raised intracra- cluded (even if there was also hydrocephalus). nial pressure (headache, vomiting, and papil- Those with ventriculitis were also excluded. Table 1 loedemal) is rare in children with progressive shows the underlying aetiologies in the 107 cases. hydrocephalus. There are few studies of the clinical Hydrocephalus associated with spina bifida and presentation of hydrocephalus with raised intracra- idiopathic hydrocephalus were the most common nial pressure either before or after an operation to presentation (65%).
    [Show full text]
  • Transjugular Intrahepatic Portosystemic Stent-Shunt In
    Guidelines Transjugular intrahepatic portosystemic stent-shunt in Gut: first published as 10.1136/gutjnl-2019-320221 on 29 February 2020. Downloaded from the management of portal hypertension Dhiraj Tripathi ,1,2,3 Adrian J Stanley ,4 Peter C Hayes ,5 Simon Travis,6 Matthew J Armstrong ,1,2,3 Emmanuel A Tsochatzis ,7 Ian A Rowe ,8 Nicholas Roslund,9 Hamish Ireland ,10 Mandy Lomax,11 Joanne A Leithead,12 Homoyon Mehrzad,13 Richard J Aspinall ,14 Joanne McDonagh,1 David Patch7 For numbered affiliations see ABSTRact ► In secondary prevention of oesophageal end of article. These guidelines on transjugular intrahepatic variceal bleeding, TIPSS can be considered portosystemic stent- shunt (TIPSS) in the management where patients rebleed despite combination of Correspondence to of portal hypertension have been commissioned by the VBL +NSBB taking into account the severity Dr Dhiraj Tripathi, Liver Unit, University Hospitals Birmingham Clinical Services and Standards Committee (CSSC) of of rebleeding and other complications of portal NHS Foundation Trust, the British Society of Gastroenterology (BSG) under the hypertension, with careful patient selection Birmingham B15 2TH, UK; auspices of the Liver Section of the BSG. The guidelines to minimise hepatic encephalopathy (weak d. tripathi@ bham. ac. uk are new and have been produced in collaboration with recommendation, moderate- quality evidence). Received 2 November 2019 the British Society of Interventional Radiology (BSIR) Further large controlled trials are required to Revised 20 January 2020 and British Association of the Study of the Liver (BASL). investigate the role of TIPSS as first- line therapy Accepted 22 January 2020 The guidelines development group comprises elected in secondary prevention (strong recommenda- members of the BSG Liver Section, representation tion, low quality of evidence).
    [Show full text]